



Uterine Malignant and Potentially Malignant Mesenchymal Tumours Histopathology Reporting Guide

Family/Last name

Date of birth

Given name(s)

Patient identifiers

Date of request

Accession/Laboratory number

Elements in **black text** are CORE. Elements in **grey text** are NON-CORE.

indicates multi-select values indicates single select values

[SCOPE OF THIS DATASET](#)

CLINICAL INFORMATION (select all that apply)

Information not provided

History of previous cancer, *specify*

History of previous gynecologic biopsy/surgical excision, *specify*

Other, *specify*

OPERATIVE PROCEDURE (select all that apply)

Not specified

Hysterectomy

Simple total

Simple supracervical/subtotal

Radical

Type not specified

Myomectomy

Lymph nodes, *specify site(s)*

Other, *specify*

SPECIMEN INTEGRITY

Intact

Non-intact

Morcellated/fragmented

Opened

SPECIMEN(S) SUBMITTED (select all that apply)

None submitted

Ovaries

Left

Right

Not specified

Fallopian tubes

Left

Right

Not specified

Omentum

Peritoneal biopsies, *specify site(s)*

Peritoneal washings/peritoneal fluid

Lymph nodes, *specify site(s)*

Other, *specify*

TUMOUR SITE (select all that apply)

Indeterminate

Cervix

Lower uterine segment

Corpus

Other, *specify*

MAXIMUM TUMOUR DIMENSION

mm

Cannot be assessed, *specify*

BLOCK IDENTIFICATION KEY

(List overleaf or separately with an indication of the nature and origin of all tissue blocks)

HISTOLOGICAL TUMOUR TYPE 

(Value list based on the World Health Organization Classification of Female Genital Tumours (2020))

- Smooth muscle tumour of uncertain malignant potential (STUMP)
- Leiomyosarcoma
- Endometrial stromal sarcoma, low grade
- Endometrial stromal sarcoma, high grade
- Undifferentiated uterine sarcoma
- Mullerian adenosarcoma without sarcomatous overgrowth
- Mullerian adenosarcoma with sarcomatous overgrowth
- Uterine tumour resembling ovarian sex cord tumour (UTROSCT)
- Perivascular epithelioid cell tumour (PEComa)
- Inflammatory myofibroblastic tumour
- NTRK-rearranged sarcoma
- SMARC-deficient uterine sarcoma
- Rhabdomyosarcoma (RMS) (embryonal and pleomorphic)
- Alveolar soft part sarcoma
- Neuroendocrine neoplasm, *specify type*

Other, *specify*

MITOTIC COUNT^a 

 /mm²

Cannot be assessed

^a Core for leiomyosarcoma, STUMP, PEComa; non-core for all other entities but including mitotic count is strongly recommended.

EXTENT OF INVASION 

Myometrial or cervical stromal invasion

(Applicable to adenosarcoma only)

- Cannot be assessed
- Not identified
- ≤50%
- >50%

Uterine serosa involvement

- Cannot be assessed
- Not involved

Distance of tumour to uterine serosa mm

Involved

Parametrial involvement

- Not submitted
- Cannot be assessed
- Not involved
- Involved
 - Left
 - Right
 - Indeterminate

Omentum^b

- Cannot be assessed
- Not involved
- Involved

Vagina^b

- Cannot be assessed
- Not involved
- Involved

Fallopian tube^b

- Cannot be assessed
- Not involved
- Involved
 - Left
 - Right
 - Indeterminate

Ovary^b

- Cannot be assessed
- Not involved
- Involved
 - Left
 - Right
 - Indeterminate

Peritoneal biopsies^b

- Not involved
- Involved

Peritoneal washings/peritoneal fluid^b

- Positive
- Negative
- Atypical/suspicious

^b If received.

LYMPHOVASCULAR INVASION 

- Indeterminate
- Not identified
- Present

MARGIN STATUS 

Distal/cervical or vaginal

- Cannot be assessed
- Not involved

Distance of tumour from closest cervical or vaginal margin mm

Specify closest margin, if possible

Involved

Specify margin, if possible

- Cervical
- Vaginal
- Other, *specify*

Parametrial

- Cannot be assessed
- Not involved
- Involved

Specify laterality, if possible

LYMPH NODE STATUS^c 

Pelvic nodes

- Cannot be assessed
- No nodes submitted or found

Number of nodes examined

Number of positive nodes

Size of maximum tumour deposit mm

Para-aortic nodes

- Cannot be assessed
- No nodes submitted or found

Number of nodes examined

Number of positive nodes

Size of maximum tumour deposit mm

Other lymph nodes removed, specify site(s)

Number of nodes examined

Number of positive nodes

Size of maximum tumour deposit mm

^c If resected.

COEXISTENT PATHOLOGY 

- None identified
- Present, specify

ANCILLARY STUDIES 

- Not performed
- Performed (select all that apply)

Immunohistochemistry, specify test(s) and result(s)

Molecular findings, specify test(s) and result(s)

Other, specify test(s) and result(s)

Representative blocks for ancillary studies, specify those blocks best representing tumour and/or normal tissue for further study

PATHOLOGICALLY CONFIRMED DISTANT METASTASIS 

- Not identified
- Present, specify site(s)

PROVISIONAL PATHOLOGICAL STAGING 

FIGO (2015 edition)^d

Leiomyosarcomas and endometrial stromal sarcomas

- I Tumour limited to uterus
 - IA Less than 5 cm
 - IB More than 5 cm
- II Tumour extends beyond the uterus, within the pelvis
 - IIA Adnexal involvement
 - IIB Involvement of other pelvic tissues
- III Tumour invades abdominal tissues (not just protruding into the abdomen)
 - IIIA One site
 - IIIB More than one site
 - IIIC Metastasis to pelvic and/or para-aortic lymph nodes
- IV Tumour invades bladder and/or rectum and/or distant metastasis
 - IVA Tumour invades bladder and/or rectum
 - IVB Distant metastasis

Adenosarcomas

- I Tumour limited to uterus
 - IA Tumour limited to endometrium/endocervix with no myometrial invasion
 - IB Less than or equal to half myometrial invasion
 - IC More than half myometrial invasion
- II Tumour extends to the pelvis
 - IIA Adnexal involvement
 - IIB Tumour extends to extrauterine pelvic tissue
- III Tumour invades abdominal tissues (not just protruding into the abdomen)
 - IIIA One site
 - IIIB More than one site
 - IIIC Metastasis to pelvic and/or para-aortic lymph nodes
- IV Tumour invades bladder and/or rectum and/or distant metastasis
 - IVA Tumour invades bladder and/or rectum
 - IVB Distant metastasis

^d Reprinted from *Int J Gynaecol Obstet.*, Volume 131(Suppl 2), Prat J, Mbatani N, Uterine sarcomas, pages S105-10, 2015, with permission from Wiley.

TNM Staging (UICC TNM 8th edition 2016)^e**TNM Descriptors** (only if applicable) (select all that apply)

- m - multiple primary tumours
 r - recurrent
 y - post-therapy

Primary tumour (pT)LEIOMYOSARCOMAS AND ENDOMETRIAL STROMAL SARCOMAS^f

- T1 Tumour limited to the uterus
 T1a Tumour 5 cm or less in greatest dimension
 T1b Tumour more than 5 cm
 T2 Tumour extends beyond the uterus, within the pelvis
 T2a Tumour involves adnexa
 T2b Tumour involves other pelvis tissues
 T3 Tumour infiltrates abdominal tissues
 T3a One site
 T3b More than one site
 N1 Metastasis to regional lymph nodes
 T4 Tumour invades bladder or rectum
 M1 Distant metastasis

ADENOSARCOMA

- T1 Tumour limited to the uterus
 T1a Tumour limited to the endometrium/endocervix
 T1b Tumour invades to less than half of the myometrium
 T1c Tumour invades more than half of the myometrium
 T2 Tumour extends beyond the uterus, within the pelvis
 T2a Tumour involves adnexa
 T2b Tumour involves other pelvis tissues
 T3 Tumour involves abdominal tissues
 T3a One site
 T3b More than one site
 N1 Metastasis to regional lymph nodes
 T4 Tumour invades bladder or rectum
 M1 Distant metastasis

Regional lymph nodes (pN)

- NX Regional lymph nodes cannot be assessed
 N0 No regional lymph node metastasis
 N1 Regional lymph node metastasis

^e Reproduced with permission. Source: UICC TNM Classification of Malignant Tumours, 8th Edition, eds by James D. Brierley, Mary K. Gospodarowicz, Christian Wittekind. 2016, Publisher Wiley (incorporating any errata published up until 6th October 2020).

^f It is recommended that all malignant uterine mesenchymal neoplasms other than adenosarcoma be staged using the staging system for leiomyosarcomas and endometrial stromal sarcomas.